Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn
Drugmaker’s potential acquisition of Ollin Biosciences is latest in glut of deals in biotechnology sector
We haven't written up this one. Financial Times has the full story — the link below goes straight to it.